eFT508

eFT508 is a potent and highly selective inhibitor of the mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1/2), key regulators of mRNA translation protein eukaryotic initiation factor eIF4E.1 It potently inhibits phosphorylation of eIF4E in multiple solid and hematological tumor lines leading to blockade of pro-inflammatory and pro-tumorigenic cytokine production. Displays inhibitory effects in various cancers models including acute myeloid leukemia, gastric, and breast. eFT-508 has also shown efficacy in treating neuropathic pain via the MNK-eIF4E pathway.